Published Date: 08 Mar 2023
The latest data on metformin in COVID show benefits in the disease.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Novel biomarkers may improve diagnosis of gallbladder cancer
2.
A new blood test greatly increases the ability to detect cancer.
3.
Survival rates for incurable larynx cancer investigated for first time
4.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
5.
Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity
1.
Navigating the Complexities of Melanoma Staging: A Comprehensive Guide
2.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
3.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
4.
IL1R2 Inhibition: A New Strategy to Boost Cancer Immunity
5.
Octreotide's Efficacy in Reducing Transfusion Requirements in Angiodysplasia Bleeding
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
2.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation